Turkiye Klinikleri Journal of Sports Sciences

.: REVIEW
Sporda Damar Mekanizmasını Etkileyen Genetik Faktörler: Geleneksel Derleme
Genetic Factors Affecting the Vascular Mechanism in Sports: Traditional Review
Sedat KAHYAa
aOndokuz Mayıs Üniversitesi Spor Bilimleri Fakültesi, Beden Eğitimi ve Spor ABD, Samsun, Türkiye
Turkiye Klinikleri J Sports Sci. 2023;15(2):331-40
doi: 10.5336/sportsci.2022-94433
Article Language: TR
Full Text
ÖZET
 Mevcut çalışmamız, sporda genetik etmenlerin damar mekanizması üzerindeki etkisini incelemek amacıyla yapılmıştır. Damarlar, sportif performansın etkili ve verimli bir şeklide sürdürülmesinde anahtar bir role sahip olabilir. Anjiyogenez, mevcut damarlardan birtakım fizyolojik süreçler yoluyla yeni damar oluşumudur. Mevcut çalışmamız, bugüne kadar VEGFA, HIF-1A, ACE ve NOS3 genleri ile ilgili NCBI veri tabanına kayıtlı; PubMed arama motoru ile Google Akademik, ResearchGate, MPDI, Academia, GeneCards, Semantic Scholar, MLTJ Online ve Genetic Applications veri tabanlarına kayıtlı çalışmaların özetlenmesini içermektedir. Çalışmamızda, damar anjiyogenezini stimüle eden gen yapılarının hipoksiye karşı geliştirdiği mekanizma sayesinde damar anjiyogenezini artırdığı sonucuna ulaşılmıştır. Bu amaçla HIF-1A geni, hem patolojik yönden hem de fizyolojik yönden bir etkiye sahip olabilir. Özellikle oksijenin yetersiz olduğu durumlarda aktif hâle geçen HIF-1A geni, diğer birçok gen için önemli bir biyolojik yapıdır. Çalışmamızda, kardiyovasküler sistemin egzersize tepki olarak verdiği yanıtta anjiyotensin dönüştürücü enzim aktivitesinin damarların daralmasını sağlayarak damar içi basıncı artırdığı, bu durumun da maksimal kuvvet/güç sporlarında sporculara avantaj sağladığı görülmüştür. ACE geninin endotel üzerindeki degradasyonunun birey sağlığını olumsuz bir şekilde etkileyebileceği ve NOS3 ile VEGFA genlerinin, endotelin varlığında damar iç yüzeylerinde oluşturduğu vazodilatasyonun özellikle dayanıklılık sporlarında önemli bir regülatör olabileceği mevcut çalışmamız sonucunda gözlemlenmiştir. Sonuç olarak kardiyovasküler sistem, genetik faktörlerden etkilenerek sportif performansın gelişimine olumlu katkılar sağlayabilmektedir.

Anahtar Kelimeler: Anjiyogenez; endotel; gen; hipoksi; spor
ABSTRACT
 Our study was conducted to investigate the effect of genetic factors on vascular mechanism in sports. Veins could play a key role in maintaining sports performance effectively and efficiently. Angiogenesis was the formation of new vessels from existing vessels through a number of physiological processes. It includes a summary of studies registered in Google Scholar, ResearchGate, MPDI, Academia, GeneCards, Semantic Scholar, MLTJ Online, Genetic Applications and PubMed engine that has been registered in the NCBI database regarding VEGFA, HIF-1A, ACE and NOS3 genes to date. It was concluded that gene structures that stimulate vascular angiogenesis increase angiogenesis thanks to the mechanism developed against hypoxia. The HIF-1A gene has both a pathological/physiological effect. The HIF-1A gene, which is activated especially in cases where oxygen is insufficient, is an important biological structure for many genes. It observes that angiotensin converting enzyme activity increases the intravascular pressure by constricting the vessels in the response of the cardiovascular system to exercise, and in this case, it provides an advantage to the athletes in maximal strength sports. It was seen degradation of the ACE gene on the endothelium may adversely affect individual health. It observes that NOS3 and VEGFA genes may be an important regulator, especially in endurance exercises, in the vasodilation mechanism that they form on the inner surfaces of the vessels in the presence of endothelium. Result, the cardiovascular system can make positive contributions to the development of sports performance by being affected by genetic factors.

Keywords: Angiogenesis; endothelial; gene; hypoxia; spor
REFERENCES:
  1. Naureen Z, Perrone M, Paolacci S, Maltese PE, Dhuli K, Kurti D, et al. Genetic test for the personalization of sport training. Acta Biomed. 2020;91(13-S):e2020012. [PubMed]  [PMC] 
  2. Egesoy H, Gümüşdağ H, Kartal A. Gen dopingi ve sportif performans [Gene doping and sports performance]. Hitit Üniversitesi Sosyal Bilimler Enstitüsü Dergisi. 2013;6(1):71-85. [Link] 
  3. Ulucan K, Topal ES, Aksulu BK, Yaman B, Çiftçi İC, Bıyıklı T. Atletik performans, genetik ve gen dopingi [Atletic performance, genetics and gene doping]. İKSST Dergisi. 2015;7(2):58-62. [Crossref] 
  4. Bulğay C, Çetin E, Ergün MA. Sportif performans ve BDNF ilişkisi [The relationship between athletic performance and BDNF]. GMJ. 2020;31:686-9. [Crossref] 
  5. Cerit M, Çakıroğlu T. Genetik ve atletik performans [Athletic performance and genetics]. Turan-Sam Uluslararası Bilimsel Hakemli Dergisi. 2019;11(43):494-500. [Crossref] 
  6. Demir M, Filiz K. Spor egzersizlerinin insan organizması üzerindeki etkileri [Effects of sport exercises on human organism]. Gazi Üniversitesi Kırşehir Eğitim Fakültesi. 2004;5(2):110-4. [Link] 
  7. Kılınçarslan G. Fizyolojik özel dolaşım ve egzersiz [Physiological special circulation and exercise]. Herkes için Spor ve Rekreasyon Dergisi. 2019;1(1):1-10. [Link] 
  8. Dursunoğlu N, Dursunoğlu D. Obstrüktif uyku apne sendromu, endotel disfonksiyonu ve koroner ateroskleroz [Obstructive sleep apnea syndrome, endothelial dysfunction and coronary atherosclerosis]. Tüberküloz ve Toraks Dergisi. 2005;53(3):299-306. [Link] 
  9. Yaylalı YT, Küçükaslan M. Endotel disfonksiyonu [Endothelial dysfunction]. Pamukkale Tıp Dergisi. 2011;4(3):152-7. [Link] 
  10. Akkiprik M, Çevik D, Özer A, Emerk K. Homosisteinin insan göbek kordon ven endotel hücre kültüründe eNOS ve DDAH Gen ekspresyonları üzerine etkisi [Effects of homocysteine on eNOS and DDAH gene expression levels in primary human umbilical endothelial cell culture]. Marmara Medical Journal. 2007;20(3):144-9. [Link] 
  11. İrtegün S, Ağaçayak E, Deveci E. Preeklamptik ve normotansif plasentalarda VEGF ve Vimentin ekspresyon düzeylerinin immunohistokimya ve Western Blot yöntemleri ile incelenmesi [Examining the expression level of VEGF and vimentin by immunohistochemistry and Western Blot in preeclamptic and normotensive placentas]. Dicle Tıp Dergisi. 2016;43(3):400-5. [Crossref] 
  12. Movafagh S, Raj D, Sanaei-Ardekani M, Bhatia D, Vo K, Mahmoudieh M, et al. Hypoxia inducible factor 1: a urinary biomarker of kidney disease. Clin Transl Sci. 2017;10(3):201-7. [Crossref]  [PubMed]  [PMC] 
  13. Tokyol Ç, Aktepe F, Dilek FH, Yılmazer M. Expression of vascular endothelial growth factor and matrix metalloproteinase-2 in uterine leiomyoma and correlation with angiogenesis. SDU Medical Faculty Journal. 2011;18(3):86-91. [Link] 
  14. Shnayder NA, Petrova MM, Popova TE, Davidova TK, Bobrova OP, Trefilova VV, et al. Prospects for the personalized multimodal therapy approach to pain management via action on NO and NOS. Molecules. 2021;26(9):2431. [Crossref]  [PubMed]  [PMC] 
  15. Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R, Lefer DJ. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci U S A. 2003;100(8):4891-6. [Crossref]  [PubMed]  [PMC] 
  16. GeneCards [Internet]. [Cited: September 20, 2022]. ACE, VEGFA, HIF1A, NOS3 Gen Lokasyonları. Available from: [Link] 
  17. Murthy J, Gurramkonda VB, Lakkakula S, Pathapati RM, Maram R, Lakkakula BV. Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with nonsyndromic oral clefts. Turkish Journal of Biochemistry. 2013;38(3):308-12. [Crossref] 
  18. Bayram A, İğci M, Yiğiter R, Elçi MA, Cengiz B, Öztuzcu S, et al. Multiple sklerozlu hastalarda NOS3 geninin mRNA seviyesinde ifadesi [mRNA expressions of NOS3 gene among patients with multiple sclerosis]. Firat Med J. 2014;19(1):38-42. [Link] 
  19. Ben-Zaken S, Eliakim A, Nemet D, Kaufman L, Meckel Y. Genetic characteristics of competitive swimmers: a review. Biol Sport. 2022;39(1):157-70. [Crossref]  [PubMed]  [PMC] 
  20. Gökbay İZ, Oyacı Y, Pehlivan S. NOS3 (intron 4 A/B VNTR ve rs1799983) ve PER3 (rs57875989) gen varyantlarının madde kullanım bozukluklarındaki davranış eğilimlerine etkisinin gini indeksi ve bilgi kazanım sınıflandırması algoritmalarıyla analizi [Assesment of gini index and information gain classification on predicting substance use disorders tendency related NOS3 (intron 4A/B VNTR and rs1799983) and PER3 (rs57875989) gene variants. ICONDATA'21. 2021;1(1):669-79. [Link] 
  21. Dinç N, Gökmen MH. Atletik performans ve spor genetiği [Athletic performance and sports genetics]. Manisa Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi. 2019;6(2):127-37. [Crossref] 
  22. Zmijewski P, Cięszczyk P, Ahmetov II, Gronek P, Lulińska-Kuklik E, Dornowski M, et al. The NOS3 G894T (rs1799983) and -786T/C (rs2070744) polymorphisms are associated with elite swimmer status. Biol Sport. 2018;35(4):313-9. [Crossref]  [PubMed]  [PMC] 
  23. Gronek P, Gronek J, Lulińska-Kuklik E, Spieszny M, Niewczas M, Kaczmarczyk M, et al. Polygenic study of endurance-associated genetic markers NOS3 (Glu298Asp), BDKRB2 (-9/+9), UCP2 (Ala55Val), AMPD1 (Gln45Ter) and ACE (I/D) in polish male half marathoners. J Hum Kinet. 2018;64:87-98. [Crossref]  [PubMed]  [PMC] 
  24. Mairbäurl H. Red blood cells in sports: effects of exercise and training on oxygen supply by red blood cells. Front Physiol. 2013;4:332. [Crossref]  [PubMed]  [PMC] 
  25. Jenkins NT, Landers RQ, Prior SJ, Soni N, Spangenburg EE, Hagberg JM. Effects of acute and chronic endurance exercise on intracellular nitric oxide and superoxide in circulating CD34⁺ and CD34⁻ cells. J Appl Physiol (1985). 2011;111(3):929-37. [Crossref]  [PubMed]  [PMC] 
  26. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114-27. [Crossref]  [PubMed] 
  27. Hamutoğlu R, Önder O. Fizyolojik ve patolojik koşullarda anjiyogenezin rolü [The role of angiogenesis in physiological and pathological conditions]. FNG & Bilim Tıp Transplantasyon Dergisi. 2017;2(2):56-62. [Crossref] 
  28. Liutkeviciene R, Vilkeviciute A, Gedvilaite G, Kaikaryte K, Kriauciuniene L. Haplotypes of HTRA1 rs1120638, TIMP3 rs9621532, VEGFA rs833068, CFI rs10033900, ERCC6 rs3793784, and KCTD10 rs56209061 gene polymorphisms in age-related macular degeneration. Dis Markers. 2019;2019:9602949. [Crossref]  [PubMed]  [PMC] 
  29. Soyocak A, Coşan DT, Özgen M, Kurt H, Mutlu FŞ. Primer diz osteoartrit hastalarında VEGFA ve HIF1-A gen ekspresyon seviyelerinin araştırılması [Investigation of VEGFA and HIF1-A gene expression levels in primary knee osteoarthritis patients]. Mersin Üniv Sağlık Bilim Derg. 2020;13(1):97-106. [Crossref] 
  30. Zelzer E, Mamluk R, Ferrara N, Johnson RS, Schipani E, Olsen BR. VEGFA is necessary for chondrocyte survival during bone development. Development. 2004;131(9):2161-71. [Crossref]  [PubMed] 
  31. Cuzziol CI, Castanhole-Nunes MMU, Pavarino ÉC, Goloni-Bertollo EM. MicroRNAs as regulators of VEGFA and NFE2L2 in cancer. Gene. 2020;759:144994. [Crossref]  [PubMed] 
  32. Vural P. Fizyolojik ve patolojik anjiogenezde vasküler endotelyal büyüme faktörünün rolü [Role of vascular endothelial growth factor in physiological and pathological angiogenesis]. Türk Klinik Biyokimya Dergisi. 2018;16(1):53-62. [Link] 
  33. Naik NA, Bhat IA, Afroze D, Rasool R, Mir H, Andrabi SI, et al. Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India). Tumour Biol. 2012;33(3):833-9. [Crossref]  [PubMed] 
  34. Bizjak DA, Zügel M, Treff G, Winkert K, Jerg A, Hudemann J, et al. Effects of training status and exercise mode on global gene expression in skeletal muscle. Int J Mol Sci. 2021;22(22):12578. [Crossref]  [PubMed]  [PMC] 
  35. Silvennoinen M, Ahtiainen JP, Hulmi JJ, Pekkala S, Taipale RS, Nindl BC, et al. PGC-1 isoforms and their target genes are expressed differently in human skeletal muscle following resistance and endurance exercise. Physiol Rep. 2015;3(10):e12563. [Crossref]  [PubMed]  [PMC] 
  36. Lulińska-Kuklik E, Leźnicka K, Humińska-Lisowska K, Moska W, Michałowska-Sawczyn M, Ossowski Z, et al. The VEGFA gene and anterior cruciate ligament rupture risk in the Caucasian population. Biol Sport. 2019;36(1):3-8. [Crossref]  [PubMed]  [PMC] 
  37. Shukla M, Gupta R, Pandey V, Rochette J, Dhandapany PS, Tiwari PK, et al. VEGFA promoter polymorphisms rs699947 and rs35569394 are associated with the risk of anterior cruciate ligament ruptures among Indian athletes: a cross-sectional study. Orthop J Sports Med. 2020;8(12):2325967120964472. [Crossref]  [PubMed]  [PMC] 
  38. Brazier J, Antrobus M, Stebbings GK, Day SH, Heffernan SM, Cross MJ, et al. Tendon and ligament injuries in elite rugby: the potential genetic ınfluence. Sports (Basel). 2019;7(6):138. [Crossref]  [PubMed]  [PMC] 
  39. Karagenç N, Meydancı D, Küçüksayan H. Akciğer kanseri hücre dizilerinde hipoksi indüklenebilir faktör-1 (HIF-1) ve paraoksonaz enzim ilişkisinin araştırılması [Association of hypoxia inducible factor 1 (HIF-1) and paraoxonase enzyme in lung cancer cell lines]. Dicle Tıp Dergisi. 2015;42(3):361-7. [Crossref] 
  40. Pasiakos SM, Berryman CE, Carrigan CT, Young AJ, Carbone JW. Muscle protein turnover and the molecular regulation of muscle mass during hypoxia. Med Sci Sports Exerc. 2017;49(7):1340-50. [Crossref]  [PubMed] 
  41. Demirel SH, Çetinkaya S. Hipoksiyle indüklenen faktör-1: hücrenin hipoksiye fizyolojik ve patolojik cevabı [Physiological and pathological response to hypoxia of cell]. Sakaryamj. 2014;4(4):172-7. [Crossref] 
  42. Güran Ş. Kalp yetmezliğinde anjiyogenesiz ve gen tedavisi [Angiogenesis and gene therapy in heart failure]. Gülhane Tıp Dergisi. 2004;46(1):84-7. [Link] 
  43. Tepebaşı MY, Calapoğlu NŞ. Hipoksi ile indüklenen faktör-1 alfa (HIF-1 α) C111A gen polimorfizmi ile hemoglobin konsantrasyonu arasınadaki ilişkinin araştırılması [Hypoxia-induced factor-1 alpha (HIF-1 α) Between C111A gene polymorphism and hemoglobin concentration investigation of the relationship]. SDÜ Tıp Fak Derg. 2016;23(2):53-9. [Link] 
  44. Lippi G, Franchini M, Guidi GC. Blood doping by cobalt. Should we measure cobalt in athletes? J Occup Med Toxicol. 2006;1:18. [Crossref]  [PubMed]  [PMC] 
  45. Calapoğlu NŞ. Hipoksiye karşı hücresel cevabın düzenleyicisi: HIF-1 [Regulator of cellular response to hypoxia] Smyrna Tıp Dergisi. 2016;48:1-6. [Link] 
  46. Cicavoğlu HE, Kaya C, Cerit M. Effects of genetic factors on high altitude training performance. Genetics & Applications. 2021;5(1):2-9. [Crossref] 
  47. Çetin E, Çolak M, Ateşoğlu U. Kayaklı koşucularda dayanıklılık egzersizlerinin normoksi ve hipoksi koşullarında maksimum oksijen tüketimi (MaxVO2) ve bazı solunum parametreleri üzerine etkisi [The effect of endurance training in the conditions of normoxia and hypoxia on maximal oxygen consumption (VO2max) and some ventilator parameters in cross-country skiers]. Fırat Tıp Dergisi. 2008;13(1):18-23. [Link] 
  48. Akgül MŞ, Baydil B, Gürses VV, Karabıyık H, Koz M. Normoksik ve hipoksik koşullarda uygulanan yüksek şiddetli interval antrenman programının kan yağ parametreleri üzerine etkisi [The effect of high intensity interval training programme in blood lipid parameters on normoxic and hypoxic conditions]. Uluslararası Kültürel ve Sosyal Araştırmalar Dergisi. 2018;4(1):130-8. [Link] 
  49. Gabbasov RT, Arkhipova AA, Borisova AV, Hakimullina AM, Kuznetsova AV, Williams AG, et al. The HIF1A gene Pro582Ser polymorphism in Russian strength athletes. J Strength Cond Res. 2013;27(8):2055-8. [Crossref]  [PubMed] 
  50. Cieszczyk P, Eider J, Arczewska A, Ostanek M, Leońska-Duniec A, Sawczyn S, et al. The HIF1A gene Pro582Ser polymorphism in Polish power-orientated athletes. Biol Sport. 2011;28:111-4. [Crossref] 
  51. Başar Y, Ayalp K. Venöz tromboembolizmin plazma ACE düzeyleri ve ACE gen polimorfizmi ile ilişkisi [The relationship of venous thromboembolism with plasma ace levels and ace gene polimorphism]. Turkish J Vasc Surg. 2006;15(1):1-6. [Link] 
  52. Yıldırım ME, Koçak N, Özen F, Özdemir Ö. Anjiotensin dönüştüren enzim (ACE) insersiyon/delesyon (I/D) gen polimorfizmi [Angiotensin converting enzyme (ACE) insertion/deletion (I/D) gene polymorphism]. Journal of Turgut Ozal Medical Center. 2010;17(1):15-8. [Link] 
  53. Akgül M, Ünlüişler Ş, Karaca D. Genetik yapının sportif performansa etkisi [The effect of genetic structures' on sports performance]. Social and Human Scientific. 2018;1(3):424-37. [Crossref] 
  54. Sezer S, Altınışık J, Bozkurt N, Akkanet S, Ateş HÖ. Migrende anjiyotensin enzim (ACE) insertiyon/delesyon (I/D) gen polimorfizmin analizi [Analysis of angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism in migraine]. Çağdaş Tıp Dergisi. 2013;3(1):7-11. [Link] 
  55. Ginevičienė V, Utkus A, Pranckevičienė E, Semenova EA, Hall ECR, Ahmetov II. Perspectives in sports genomics. Biomedicines. 2022;10(2):298. [Crossref]  [PubMed]  [PMC] 
  56. Maffulli N, Margiotti K, Longo UG, Loppini M, Fazio VM, Denaro V. The genetics of sports injuries and athletic performance. Muscles Ligaments Tendons J. 2013;3(3):173-89. [PubMed]  [PMC] 
  57. Oruç N, Lamb J, Whitcomb DJ, Sass DA. The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC. Turk J Gastroenterol. 2008;19(4):250-3. [PubMed] 
  58. Sayın BE, Bayram B, Türkoğlu Z, Keleştemur Ü, Mutlu F. Angiotensin converting enzyme (ACE) gene I/D polymorphism genotypes and ACE levels of serum and synovial fluid of patients with osteoarthritis. Pharm Sci. 2009;34:77-81. [Link] 
  59. Sticchi E, Sofi F, Romagnuolo I, Pratesi G, Pulli R, Pratesi C, et al. eNOS and ACE genes influence peripheral arterial disease predisposition in smokers. J Vasc Surg. 2010;52(1):97-102.e1. [Crossref]  [PubMed] 
  60. Sercan C, Eken BF, Erel Ş, Ülgüt D, Kapıcı S, Ulucan K. Spor genetiği ve ACE gen ilişkisi [The relationship of sports genetics and ACE gene]. İnönü Üniversitesi, Beden Eğitimi ve Spor Bilimleri Dergisi. 2016;3(2):26-34. [Link] 
  61. Bae JS, Kang BY, Lee KO, Lee ST. Genetic variation in the renin-angiotensin system and response to endurance training. Med Princ Pract. 2007;16(2):142-6. [Crossref]  [PubMed] 
  62. Varillas-Delgado D, Del Coso J, Gutiérrez-Hellín J, Aguilar-Navarro M, Mu-oz A, Maestro A, et al. Genetics and sports performance: the present and future in the identification of talent for sports based on DNA testing. Eur J Appl Physiol. 2022;122(8):1811-30. [Crossref]  [PubMed]  [PMC] 
  63. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H, et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 1997;96(3):741-7. [Crossref]  [PubMed] 
  64. Bosnyák E, Trájer E, Udvardy A, Komka Z, Protzner A, Kováts T, et al. ACE and ACTN3 genes polymorphisms among female Hungarian athletes in the aspect of sport disciplines. Acta Physiol Hung. 2015;102(4):451-8. [Crossref]  [PubMed] 
  65. Chen Y, Wang D, Yan P, Yan S, Chang Q, Cheng Z. Meta-analyses of the association between the PPARGC1A Gly482Ser polymorphism and athletic performance. Biol Sport. 2019;36(4):301-9. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com